| William Coleman Sharp, MD | |
|
21700 Northwestern Hwy, 600, Southfield, MI 48075-4906 | |
| (248) 559-6664 | |
| (248) 559-5628 |
| Full Name | William Coleman Sharp |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 49 Years |
| Location | 21700 Northwestern Hwy, Southfield, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053312983 | NPI | - | NPPES |
| 350039810 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 4301036715 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Universal Home Health Care | Southfield, MI | Home health agency |
| Ascension Providence Hospital, Southfield And Novi | Southfield, MI | Hospital |
| Ascension St John Hospital | Detroit, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ascension Providence Hospital | 6103738703 | 181 |
News Archive
The final results of a six-month, multi-center, open-label Phase 3 study of VIAject® (more-rapid-acting injectable human insulin) versus regular human insulin (RHI) in 471 patients with type 2 diabetes were presented today by Helena Rodbard, M.D., at the 70th Scientific Sessions of the American Diabetes Association. Dr. Rodbard was a principal investigator of this study, which was designed to evaluate the safety and efficacy of VIAject® versus regular human insulin when used in combination with insulin glargine.
GlaxoSmithKline has announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria (albiglutide) in men and women with type 2 diabetes.
Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer. That's according to a University of Colorado Cancer Center study published in the April issue of Cancer, the official journal of the American Cancer Society.
Researchers at Queen's have found that spending large amounts of time sitting or lounging around during the day is linked to around 70,000 deaths per year in the UK.
TeleHealth Services and UbiCare announce an exclusive business partnership that provides a unique, proven patient education and engagement solution for hospitals, healthcare systems, clinics and ambulatory centers.
› Verified 7 days ago
| Entity Name | Ascension Providence Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942265236 PECOS PAC ID: 6103738703 Enrollment ID: O20031103000326 |
News Archive
The final results of a six-month, multi-center, open-label Phase 3 study of VIAject® (more-rapid-acting injectable human insulin) versus regular human insulin (RHI) in 471 patients with type 2 diabetes were presented today by Helena Rodbard, M.D., at the 70th Scientific Sessions of the American Diabetes Association. Dr. Rodbard was a principal investigator of this study, which was designed to evaluate the safety and efficacy of VIAject® versus regular human insulin when used in combination with insulin glargine.
GlaxoSmithKline has announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria (albiglutide) in men and women with type 2 diabetes.
Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer. That's according to a University of Colorado Cancer Center study published in the April issue of Cancer, the official journal of the American Cancer Society.
Researchers at Queen's have found that spending large amounts of time sitting or lounging around during the day is linked to around 70,000 deaths per year in the UK.
TeleHealth Services and UbiCare announce an exclusive business partnership that provides a unique, proven patient education and engagement solution for hospitals, healthcare systems, clinics and ambulatory centers.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William Coleman Sharp, MD 25925 Telegraph Rd, 210, Southfield, MI 48034-2518 Ph: (248) 746-0342 | William Coleman Sharp, MD 21700 Northwestern Hwy, 600, Southfield, MI 48075-4906 Ph: (248) 559-6664 |
News Archive
The final results of a six-month, multi-center, open-label Phase 3 study of VIAject® (more-rapid-acting injectable human insulin) versus regular human insulin (RHI) in 471 patients with type 2 diabetes were presented today by Helena Rodbard, M.D., at the 70th Scientific Sessions of the American Diabetes Association. Dr. Rodbard was a principal investigator of this study, which was designed to evaluate the safety and efficacy of VIAject® versus regular human insulin when used in combination with insulin glargine.
GlaxoSmithKline has announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria (albiglutide) in men and women with type 2 diabetes.
Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer. That's according to a University of Colorado Cancer Center study published in the April issue of Cancer, the official journal of the American Cancer Society.
Researchers at Queen's have found that spending large amounts of time sitting or lounging around during the day is linked to around 70,000 deaths per year in the UK.
TeleHealth Services and UbiCare announce an exclusive business partnership that provides a unique, proven patient education and engagement solution for hospitals, healthcare systems, clinics and ambulatory centers.
› Verified 7 days ago
Surinder Mendiratta, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 20905 Greenfield Rd, Suite 502, Southfield, MI 48075 Phone: 248-395-2888 Fax: 248-395-2891 | |
Dr. Freddy R Sosa, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 22250 Providence Dr, Suite 703, Southfield, MI 48075 Phone: 248-569-1770 Fax: 248-443-2439 | |
Kun Kil Yu, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 19189 W 10 Mile Rd, Ste 200, Southfield, MI 48075 Phone: 248-948-7985 Fax: 248-948-9031 | |
Dr. Vilma Drelichman, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 22301 Foster Winter Dr, 2nd Floor, Southfield, MI 48075 Phone: 248-552-0620 Fax: 248-552-0286 | |
Dr. Sumner Camisa, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 29829 Telegraph Road, #100, Southfield, MI 48034 Phone: 248-355-3033 Fax: 248-355-4936 | |
Talal Taher Khader, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 16001 W 9 Mile Rd, 4th Fl Fisher Ctr, Southfield, MI 48075 Phone: 248-849-8483 | |
Dr. Herman Kado, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 28625 Northwestern Hwy, Suite 150, Southfield, MI 48034 Phone: 248-587-2300 Fax: 248-945-0492 |